New obesity drug IBI362 shows promise in early trial for chinese patients

NCT ID NCT07000955

Ongoing Disease control Sponsor: Innovent Biologics (Suzhou) Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called IBI362 in 98 Chinese adults with moderate to severe obesity (BMI ≥ 32.5). Participants receive weekly injections of IBI362, tirzepatide, or a placebo for several weeks. The main goals are to check safety, side effects, and how the drug behaves in the body, while also measuring weight loss. It is an early-stage trial, so results will help decide if larger studies are warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBI362 (a drug similar to tirzepatide, given as a weekly injection)
What this could lead to: If successful, this could point toward a new weight-loss medication for people with severe obesity, offering an alternative to existing treatments.
What could go wrong: This is an early-phase trial with only 98 participants, so results may not apply to everyone. Side effects and safety are still being studied, and the drug may not prove effective or safe in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

The Affiliated Hospital of Nanjing University Medical School

Nanjing, Jiangsu, 210003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.